FDA Approves New First-Line TNBC Regimen - Quiz - MDSpire

FDA Approves New First-Line TNBC Regimen

Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.

  • By

  • Kathryn Wighton

  • June 26, 2026

  • 3 min

Share

Original Source(s)

FDA Approves New First-Line TNBC Regimen

  • by Kathryn Wighton

  • June 26, 2026

Related Content

Case Report: Long-term maternal and neonatal outcomes after nivolumab therapy in metastatic tonsillar sarcomatoid squamous cell carcinoma

Imaging features and differentiation between benign and malignant Brenner tumors in a multi-center cohort

Chemoradiation after chemotherapy for metastatic cervical cancer can provide chemo-free time